Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

NCT07397611 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
Kidney Cancer
Kidney Neoplasm
Renal Carcinoma

Interventions

DRUG: Casdatifan
DRUG: Zimberelimab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]